Gilead Sciences, Inc. (NASDAQ:GILD)

CAPS Rating: 5 out of 5

A biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.

Results 1 - 20 of 450 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar ifpt999 (< 20) Submitted: 4/29/2016 10:21:49 AM : Outperform Start Price: $90.04 GILD Score: -2.02

Low valuation multiples, nearly a 2% dividend, strong pipeline of products. Gild faces competitive pressures on it's largest Hep C product (Harvoni) which is hurting it's top line after rebates and promotions (net revenue.) However Gild still has the best Hep C portfolio on the market. This recent earnings report presents a buying opportunity.

Recs

0
Member Avatar dillbeans (26.37) Submitted: 4/22/2016 11:25:34 PM : Outperform Start Price: $101.84 GILD Score: -12.46

Greenblatt

Recs

0
Member Avatar jiggad369 (51.22) Submitted: 4/22/2016 3:02:54 PM : Outperform Start Price: $101.39 GILD Score: -11.79

Stable of Drugs and Trials

Recs

1
Member Avatar TheLibrarian (58.80) Submitted: 4/5/2016 10:29:18 PM : Outperform Start Price: $95.49 GILD Score: -8.62

Financially, Gilead is the most impressive of all the biotech companies. GILD was one of the top performing stocks of the 2000s, and with their focus and success in treating significant worldwide diseases such as HIV/AIDS, Hepatitis C, and forms of cancer, they're aligned for stronger growth than any competitors.

Recs

1
Member Avatar NHWeston102 (< 20) Submitted: 4/4/2016 9:32:25 AM : Outperform Start Price: $94.15 GILD Score: -6.17

Okay, I just wrote a pick for the wrong stock. Sigh. Anyhow. Gilead. Now acquiring a serious research firm in fatty-liver disease that will be big pig bucks long term. Coffee. Third cup. Need coffee....sorry, mates. Coffee....

Recs

0
Member Avatar ZaksDad (71.18) Submitted: 3/30/2016 12:52:13 PM : Outperform Start Price: $103.08 GILD Score: -15.07

Pro

MFO - 110 / 120 BCS spread

Recs

1
Member Avatar nhatch3353 (57.52) Submitted: 3/23/2016 4:39:31 PM : Underperform Start Price: $89.61 GILD Score: +3.71

Patent problems and trouble with cancer drug trials.

Recs

0
Member Avatar putspread (< 20) Submitted: 3/21/2016 6:45:15 PM : Outperform Start Price: $92.14 GILD Score: -5.53

This stock is trading near 52 week low and it is a solid company.

Recs

0
Member Avatar emotleyguy (39.73) Submitted: 3/19/2016 4:10:34 PM : Outperform Start Price: $90.00 GILD Score: -3.10

Just added this to my portfolio at 88 and change. I see a 130.00 in 12 months.

Recs

0
Member Avatar Breq (< 20) Submitted: 3/11/2016 1:50:50 PM : Outperform Start Price: $89.02 GILD Score: -2.95

To start off the stock is dirt cheap at a forward P/E of 7. Given the firms track record and solid pipeline that is way too cheap. It has drop in price in the last year but if Gilead keeps performing the stock price will follow. A nice time to buy.

Recs

0
Member Avatar 401ktimer1 (95.84) Submitted: 3/9/2016 3:20:01 PM : Outperform Start Price: $81.49 GILD Score: +2.82

http://www.fool.com/investing/general/2016/03/09/is-us-demand-for-new-hepatitis-c-drugs-about-to-ex.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2

Recs

0
Member Avatar reimerpdx (61.11) Submitted: 2/18/2016 11:50:16 AM : Outperform Start Price: $89.37 GILD Score: -8.57

Because of it's low P/E today and the future it has in front of it, including the pipeline, I like this stock a lot. And the fact that it's paying me a dividend while it grows is magical!

Recs

0
Member Avatar jamescnorris (< 20) Submitted: 2/13/2016 10:39:17 AM : Outperform Start Price: $88.56 GILD Score: -7.50

Strong cash flow, strong pipeline of products, currently undervalued

Recs

0
Member Avatar gameguru (33.09) Submitted: 2/12/2016 12:41:32 PM : Outperform Start Price: $89.00 GILD Score: -11.93

Competitive position is eroding, but huge cash machine ready to support expansion. Market is expecting a lot of pricing risk.

Recs

0
Member Avatar jsn1080 (29.85) Submitted: 2/8/2016 2:12:17 PM : Outperform Start Price: $84.60 GILD Score: -8.37

Incredible valuation at current price

Recs

0
Member Avatar Hugo1900 (< 20) Submitted: 1/30/2016 3:55:00 PM : Outperform Start Price: $81.93 GILD Score: +0.50

Stock is highly undervalued.

Recs

0
Member Avatar TygerSpark (< 20) Submitted: 1/29/2016 2:41:24 PM : Outperform Start Price: $82.60 GILD Score: -0.72

I don't think you would go wrong with Celgene or Gilead. I like the future prospects of both.

Recs

0
Member Avatar KEBowman (38.19) Submitted: 1/18/2016 6:05:40 PM : Outperform Start Price: $90.74 GILD Score: -12.10

a biotech super star

Recs

0
Member Avatar saile (< 20) Submitted: 1/15/2016 6:56:24 PM : Outperform Start Price: $88.57 GILD Score: -11.10

biotech growth due to worldwide demographics and increases in older age populations around the world

Recs

0
Member Avatar ffain (< 20) Submitted: 1/4/2016 7:32:15 AM : Outperform Start Price: $99.30 GILD Score: -14.08

Nice chart, healthcare is going up for sure.

Featured Broker Partners